Simplify Asset Management Inc. Invests $6.61 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Simplify Asset Management Inc. bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 385,188 shares of the biotechnology company's stock, valued at approximately $6,606,000. ADMA Biologics accounts for about 0.3% of Simplify Asset Management Inc.'s holdings, making the stock its 19th largest holding. Simplify Asset Management Inc. owned 0.16% of ADMA Biologics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after acquiring an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after purchasing an additional 700 shares in the last quarter. Mutual of America Capital Management LLC grew its stake in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after purchasing an additional 751 shares during the period. Maryland State Retirement & Pension System raised its holdings in ADMA Biologics by 1.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after purchasing an additional 897 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after buying an additional 967 shares during the period. Institutional investors own 75.68% of the company's stock.

Remove Ads

ADMA Biologics Stock Up 2.9 %

Shares of ADMA Biologics stock traded up $0.58 during midday trading on Thursday, hitting $20.28. The company had a trading volume of 2,316,129 shares, compared to its average volume of 3,361,322. The company has a 50 day moving average of $17.05 and a 200 day moving average of $18.13. The stock has a market capitalization of $4.79 billion, a P/E ratio of 72.43 and a beta of 0.60. ADMA Biologics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.